Each year millions of biological samples are processed, distributed, and stored worldwide. Currently samples such as DNA, RNA, proteins, bacteria, viruses, tissues, and other biological molecules are ...

CAMBRIDGE, MA -- Using an RNA sensor, MIT engineers have designed a new way to trigger cells to turn on a synthetic gene. Their approach could make it possible to create targeted therapies for cancer ...

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...

Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...

This work was supported by funding from New Zealand Ministry of Business Innovation and Employment, Research Trust of Victoria University of Wellington and The Hugh Green Foundation. The recent award ...

A new approach that strengthens the immune response could lead to intranasal vaccines for covid-19 and other diseases. MIT researchers have tweaked the design of mRNA-based covid-19 vaccines to ...

Two human cells making RNA made visible by the bioluminescent lantern in pink (middle image). On the left, the same cells making a fluorescent protein that’s distributed evenly throughout the two ...

The human body's roughly 30 trillion cells don't need all of their genes switched on at once. Instead, cells tightly control the activity of their genes — and recently, scientists uncovered a ...

RNA is usually portrayed as a molecule that works deep inside the cell, helping to turn genetic information into proteins.

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

Pharmaceutical start-up AIRNA has raised $90 million in an oversubscribed series A financing round. The firm aims to produce drugs that edit RNA transcripts in the body. AIRNA obtained an initial $30 ...

RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.